Dr. Cottini is an accomplished cancer research specialist with an impressive catalogue of publications, and her lab is investigating the role of CD56, CREB1, and other markers overexpressed in patients with t(4;14). The team also characterized the effects of racial disparities, and the concomitant presence of 1q+ and t(4;14) on outcomes and immune cell populations.
- Cottini F*, Rodriguez J, Hughes T, Sharma N, Guo L, Lozanski G, Liu B, Cocucci E, Yang Y, and Benson D*. “Redefining CD56 as a biomarker and therapeutic target in Multiple Myeloma”. Molecular Cancer Research. 2022, Jul 6;20(7):1083-1095. doi: 10.1158/1541-7786.MCR-21-0828. PMID: 35380709.
- Bao A, Zhao Q, Merritt E, Bumma N, Devarakonda S, Khan AM, Umyarova E, Rosko AE, Benson DM, Cottini F. Racial differences as predictors of outcomes in young patients with multiple myeloma. Blood Cancer J. 2022 Jul 27;12(7):114. doi: 10.1038/s41408-022-00708-3. PMID: 35896527; PMCID: PMC9329432.
- Bao A, Kudalkar R, Rodriguez J, Zhao Q, Sharma N, Bumma N, Devarakonda S, Khan A, Rosko AE, Umyarova E, Benson DM, and Cottini F. “Impact of Interval progression before autologous Stem Cell Transplant in patients with Multiple Myeloma”. Front. Oncol., 24 July 2023. Sec. Hematologic Malignancies. Volume 13 – 2023. https://doi.org/10.3389/fonc.2023.1216461.
- Ozga M, Zhao Q, Huric L, Miller C, Rosko A, Khan A, Umyarova E, Benson D, Cottini F. “ Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma.” Blood Cancer J. 2023 Nov 10;13(1):167. doi: 10.1038/s41408-023-00943-2. PMID: 37949844
Patents
- Compositions and methods for treating multiple myeloma - U.S. provisional patent application No. 62/074,935
- Novel targets in multiple myeloma and other disorders - WO 2014068542 A1
- STK4 inhibitors for treatment of hematological malignancies - U.S. provisional patent application No. 62/140,695